MARINUS PHARMACEUTICALS,INC. (NASDAQ:MRNS) Files An 8-K Other Events
ME Staff 8-k
MARINUS PHARMACEUTICALS,INC. (NASDAQ:MRNS) Files An 8-K Other EventsItem 8.01. Other Events.
On December4, 2018, the Company issued a press release announcing that additional data from a Phase 2 clinical trial in pediatric genetic epilepsies were presented at the American Epilepsy Society Annual Meeting. A copy of the press release is filed as Exhibit99.1 to this Current Report on Form8-K and is incorporated by reference in this Item 8.01 as though fully set forth herein.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
MARINUS PHARMACEUTICALS INC ExhibitEX-99.1 2 a18-41111_1ex99d1.htm EX-99.1 Exhibit 99.1 Marinus Pharmaceuticals Phase 2 Clinical Trial Data Show Long-term Effectiveness of Ganaxolone in Reducing Seizure Frequency in CDKL5 Deficiency Disorder Patients Predictive biomarker also identified in PCDH19-related pediatric epilepsy RADNOR,…To view the full exhibit click here About MARINUS PHARMACEUTICALS,INC. (NASDAQ:MRNS) Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings. Ganaxolone acts on the GABAA receptor, a target in the brain known for both anti seizure and anti anxiety effects through positive allosteric modulation. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy.
